Skip to main content

Acute Hypoxemic Respiratory Failure

Respiratory
0
Pipeline Programs
5
Companies
4
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Respiratory is a $39.4B mature market dominated by established inhalers and combination therapies with significant patent cliff risk.

$39.4B marketMature→ Stable30 products15 companies

Key Trends

  • Consolidation around GSK's triple-therapy franchises (Trelegy, Breo, Anoro)
  • Major patent expirations 2026-2031 creating $7.8B revenue cliff
  • High clinical trial activity (4,862 trials) suggesting pipeline innovation despite market maturity

Career Verdict

Respiratory offers stable commercial careers but limited growth upside; best for professionals seeking established markets with strong commercial infrastructure rather than innovation-driven advancement.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISGrowing
$18.3B
Bristol Myers Squibb·Launch15.0yr
#3TRELEGY ELLIPTADeclining
$4.5B
GSK·Peak4.9yr
#4CREONDeclining
$1.5B
AbbVie·Approaching LOE
#5BREO ELLIPTADeclining
$1.4B
GSK·Peak4.9yr

Drug Class Breakdown

FXa Inhibitors
$18.3B(46%)

dominant market driver

Unknown/Undisclosed Mechanism
$9.7B(25%)

fragmented portfolio

GLP-1 Receptor Agonists
$7.4B(19%)

rapidly expanding

Pancreatic Enzymes
$1.5B(4%)

legacy product

Corticosteroid/LABA Combinations
$796M(2%)

patent cliff approaching

Long-Acting Muscarinic Antagonists
$456M(1%)

mature maintenance therapy

Career Outlook

Stable

Respiratory is a stable, mature market suitable for commercial and medical affairs professionals seeking established career paths, but offers limited growth or innovation-focused opportunities. The impending patent cliff ($7.8B+ revenue at risk 2026-2031) will drive near-term restructuring and consolidation, potentially reducing headcount in 2027-2028. Professionals should expect strong compensation in Medical Affairs and field roles but limited advancement into strategic or R&D positions.

Breaking In

New graduates should prioritize commercial, field-based, or Medical Affairs roles over R&D; respiratory offers structured training and stable compensation but limited innovation exposure, so pair this experience with cross-therapeutic skill-building for long-term mobility.

For Experienced Professionals

Experienced professionals should evaluate whether to maximize earnings in this mature, stable market or transition to higher-growth areas (oncology, cell therapy); respiratory consolidation 2027-2030 will reduce senior-level opportunities, so consider strategic moves before patent cliff impacts headcount.

In-Demand Skills

Commercial execution and territory managementMedical Affairs/Key Opinion Leader engagementRegulatory affairs and lifecycle managementInhalation device expertise and product trainingManaged care and payer negotiations

Best For

Brand ManagerMedical Science LiaisonRegional Sales ManagerField Medical RepresentativePayer Relations ManagerRegulatory Specialist

Hiring Landscape

$84K-$314K

The respiratory sector shows modest hiring momentum (510 jobs across tracked positions) concentrated in commercial and engineering roles, with AstraZeneca and GSK leading. Medical Affairs positions command premium salaries ($314K avg) but represent only 3% of openings, reflecting the mature market's focus on sales execution over innovation. Hiring velocity is moderate and reflects market consolidation rather than expansion, suggesting limited career progression opportunities for early-to-mid career professionals.

510
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

43Stable
70Growing
45Stable
15Stable

By Department

Commercial(23%)
$122K
Engineering(11%)
$111K
Medical Affairs(3%)
$314K
IT(4%)
$84K
Manufacturing(3%)

Respiratory hiring favors commercial and field-based roles over R&D; Medical Affairs roles offer premium compensation but are scarce, making this area competitive for specialized talent.

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Eppendorf
EppendorfGermany - Hamburg
1 program
Awake Prone PositioningN/A1 trial
Active Trials
NCT06931938Recruiting342Est. Jun 2027
Hamilton medical
Hamilton medicalSwitzerland - Bonaduz
1 program
Closed-loop FiO2 controllerN/A1 trial
Active Trials
NCT06374589Recruiting50Est. May 2026
Lungpacer Medical
Lungpacer MedicalBC - Vancouver
1 program
Lungpacer AeroPace Protect SystemN/A1 trial
Active Trials
NCT05465083Completed20Est. Nov 2023
Philips
PhilipsNetherlands - Amsterdam
1 program
Protocol using end-tidal oxygen monitoring during preoxygenation before intubationN/A1 trial
Active Trials
NCT06198504Unknown72Est. May 2025

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
EppendorfAwake Prone Positioning
Hamilton medicalClosed-loop FiO2 controller
PhilipsProtocol using end-tidal oxygen monitoring during preoxygenation before intubation
Lungpacer MedicalLungpacer AeroPace Protect System

Clinical Trials (4)

Total enrollment: 484 patients across 4 trials

NCT06931938EppendorfAwake Prone Positioning

Awake Prone Positioning in Spontaneous Breathing Patients With Acute Hypoxic Respiratory Failure Due to Pneumonia

Start: Apr 2025Est. completion: Jun 2027342 patients
N/ARecruiting
NCT06374589Hamilton medicalClosed-loop FiO2 controller

Closed-Loop O2 Use During High Flow Oxygen Treatment of Critical Care Adult Patients (CLOUDHFOT)

Start: Mar 2024Est. completion: May 202650 patients
N/ARecruiting
NCT06198504PhilipsProtocol using end-tidal oxygen monitoring during preoxygenation before intubation

Impact of End-tidal Oxygen Monitoring During Preoxygenation Before Intubation for Acute Hypoxemic Respiratory Failure in ICU Setting

Start: Jan 2024Est. completion: May 202572 patients
N/AUnknown
NCT05465083Lungpacer MedicalLungpacer AeroPace Protect System

Feasibility of Transvenous Phrenic Nerve Stimulation for Diaphragm Protection in Acute Respiratory Failure

Start: Feb 2023Est. completion: Nov 202320 patients
N/ACompleted

Related Jobs in Respiratory

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 484 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.